spironolactone has been researched along with Polycystic Ovary Syndrome in 117 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with metformin alone, metformin combined with spironolactone therapy may be more effective in reducing BMI and serum androgen levels, but the combination showed no significant effect on the hirsutism score or gonadotropin hormone levels, and was not associated with an elevation in side-effects." | 9.41 | Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. ( Huang, L; Huang, S; Ren, W; Wu, J; Ye, Y; Zeng, H; Zhang, Y; Zhou, L, 2023) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 9.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 9.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS." | 9.20 | Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. ( Jongwutiwes, T; Leelaphiwat, S; Lertvikool, S; Rattanasiri, S; Sukprasert, M; Tabcharoen, C; Weerakiet, S, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin." | 9.17 | Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. ( Ganie, MA; Gupta, N; Khurana, ML; Kulshrestha, B; Mir, FA; Mudasir, S; Nisar, S; Shah, PA; Shah, ZA; Taing, S; Wani, TA; Zargar, MA, 2013) |
| "The aim of the study was to compare the effect of spironolactone (antagonist of mineralocorticoid and androgen receptors) versus spironolactone plus licorice (agonist of mineralocorticoid receptors and mild inhibitor of androgen synthesis) on plasma renin activity, aldosterone and androgen levels in women with polycystic ovary syndrome (PCOS)." | 9.12 | Treatment of polycystic ovary syndrome with spironolactone plus licorice. ( Armanini, D; Bertoldo, A; Bonanni, G; Castello, R; Faccini, G; Fiore, C; Moghetti, P; Pellati, D; Scaroni, C, 2007) |
| "We compared the efficacy of spironolactone (50 mg/d) with metformin (1000 mg/d) after random allocation in 82 adolescent and young women with polycystic ovary syndrome (PCOS) on body mass index (BMI), waist-to-hip ratio, blood pressure, menstrual cyclicity, hirsutism, hormonal levels, glycemia, and insulin sensitivity at baseline and at the 3rd and 6th months of treatment." | 9.11 | Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. ( Ammini, AC; Dwivedi, SN; Eunice, M; Ganie, MA; Gulati, M; Gupta, N; Khurana, ML, 2004) |
| "To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)." | 9.11 | Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005) |
| "This prospective clinical trial was designed to assess the effects of a long-term therapy with spironolactone, with and without dietary-induced weight-loss, on clinical features, lipid profile and insulin levels in women with polycystic ovary syndrome (PCOS)." | 9.11 | Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. ( Armanini, D; Baro, G; Benedini, S; Mantero, F; Sartorato, P; Scaroni, C; Zulian, E, 2005) |
| "To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months." | 9.09 | Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000) |
| "To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone." | 8.82 | Spironolactone for hirsutism in polycystic ovary syndrome. ( Christy, NA; Cross, LB; Franks, AS, 2005) |
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 8.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| "The impact of low-dose spironolactone (LSPL) on polycystic ovarian syndrome (PCOS)-associated cardio-renal disorder is unknown." | 8.12 | Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. ( Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU, 2022) |
| "Altogether, the present study suggests that low-dose spironolactone confers protection against adipose dysfunction in experimental PCOS animals by attenuating inflammation, oxidative stress and cellular apoptosis." | 8.12 | Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. ( Areloegbe, SE; Olaniyi, KS; Oyeleke, MB; Peter, MU, 2022) |
| "Spironolactone (SP) is an effective treatment for polycystic ovary syndrome (PCOS), but it is often associated with menstrual abnormalities whose mechanism is still under investigation." | 7.83 | Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. ( Ambrosini, G; Andrisani, A; Armanini, D; Bordin, L; Boscaro, M; Donà, G; Ragazzi, E; Sabbadin, C; Zermiani, M, 2016) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period." | 7.75 | Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. ( Abbasi, M; Esteghamati, A; Hamidi, S; Nakhjavani, M; Nosratian-Jahromi, S; Pasalar, P, 2009) |
| "The research here reported concerns 9 hirsute women, four of them with PCO and five with idiopathic hirsutism, who underwent treatment with spironolactone." | 7.67 | Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. ( Ambrosio, GB; De Salvia, D; Gangemi, M; Grandesso, R; Meneghetti, G; Nardelli, GB; Predebon, O; Spandri, P, 1984) |
| "The authors examined the effect of three months' treatment with spironolactone in 34 women with polycystic ovary syndrome." | 7.66 | Therapeutic effects of spironolactone in polycystic ovary syndrome. ( Kirschner, MA; Milewicz, A; Silber, D, 1983) |
| "Clinical and endocrine evaluations of 39 patients with hirsutism were performed to determine the effectiveness and site(s) of action of an antiandrogenic compound, spironolactone." | 7.66 | Treatment of hirsutism with spironolactone. ( Cumming, DC; Rebar, RW; Yang, JC; Yen, SS, 1982) |
| "Marked improvement in the severe hypertension (250/150 mmHg) and hirsutism of a patient suffering from polycystic ovary syndrome was quickly achieved by the use of spironolactone 200 mg per day." | 7.66 | Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. ( Blum, I; Chovers, I; Kaufman, H; Marilus, R; Rusecki, Y, 1981) |
| "Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)." | 7.66 | Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981) |
| " Thus, the primary objective of this study was to assess the effects on arterial function and structure of an OC containing chlormadinone acetate (2 mg) and ethinylestradiol (30 mcg), alone or combined with spironolactone (OC+SPL), in patients with PCOS." | 6.77 | The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. ( de Sá, MF; dos Reis, RM; Fernandes, JB; Ferriani, RA; Martins, WP; Soares, GM; Vieira, CS, 2012) |
| "Treatment with spironolactone normalized endothelial function and improved cholesterol levels in non-obese PCOS patients." | 6.76 | Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. ( Pfeifer, M; Prezelj, J; Sebestjen, M; Studen, KB, 2011) |
| "Spironolactone (SPL) is a mineralocorticoid receptor (MR) blocker that has been in wide clinical use for some decades." | 5.56 | Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe. ( Adeyanju, OA; Agbana, RD; Falodun, TO; Michael, OS; Oyewole, AL; Soetan, OA, 2020) |
| " Spironolactone (100 mg/daily) exhibited a significant reduction in FG score in idiopathic hirsutism compared to finasteride (MD: -2." | 5.41 | Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis. ( Asrar, MM; Bashir, R; Ganie, MA; Shah, IA; Wani, IA, 2023) |
| "Compared with metformin alone, metformin combined with spironolactone therapy may be more effective in reducing BMI and serum androgen levels, but the combination showed no significant effect on the hirsutism score or gonadotropin hormone levels, and was not associated with an elevation in side-effects." | 5.41 | Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. ( Huang, L; Huang, S; Ren, W; Wu, J; Ye, Y; Zeng, H; Zhang, Y; Zhou, L, 2023) |
| "The aim of this study was to compare the efficacy and safety of adding metformin or spironolactone to rosiglitazone in women with polycystic ovary syndrome (PCOS)." | 5.34 | Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. ( Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA, 2020) |
| "Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome." | 5.27 | Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. ( Burke, CW; Evans, DJ, 1986) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 5.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 5.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS." | 5.20 | Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. ( Jongwutiwes, T; Leelaphiwat, S; Lertvikool, S; Rattanasiri, S; Sukprasert, M; Tabcharoen, C; Weerakiet, S, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin." | 5.17 | Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. ( Ganie, MA; Gupta, N; Khurana, ML; Kulshrestha, B; Mir, FA; Mudasir, S; Nisar, S; Shah, PA; Shah, ZA; Taing, S; Wani, TA; Zargar, MA, 2013) |
| "The present study was designed to determine the effect of oral contraceptives (OCP) and OCP plus spironolactone (Sp) on plasma soluble CD40L levels in polycystic ovary syndrome (PCOS) patients." | 5.14 | Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. ( Alacacioglu, A; Bilgir, O; Kebapcilar, AG; Kebapcilar, L; Kozaci, DL; Sari, I; Taner, CE; Yildiz, Y; Yuksel, A, 2010) |
| " Among the treatment groups, EE/CA-metformin may be a more effective therapeutic option than the other protocols and this may be due to the beneficial effect of EE/CA-metformin on insulin resistance." | 5.14 | Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. ( Alacacioglu, A; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE, 2010) |
| "The aim of the study was to compare the effect of spironolactone (antagonist of mineralocorticoid and androgen receptors) versus spironolactone plus licorice (agonist of mineralocorticoid receptors and mild inhibitor of androgen synthesis) on plasma renin activity, aldosterone and androgen levels in women with polycystic ovary syndrome (PCOS)." | 5.12 | Treatment of polycystic ovary syndrome with spironolactone plus licorice. ( Armanini, D; Bertoldo, A; Bonanni, G; Castello, R; Faccini, G; Fiore, C; Moghetti, P; Pellati, D; Scaroni, C, 2007) |
| "We compared the efficacy of spironolactone (50 mg/d) with metformin (1000 mg/d) after random allocation in 82 adolescent and young women with polycystic ovary syndrome (PCOS) on body mass index (BMI), waist-to-hip ratio, blood pressure, menstrual cyclicity, hirsutism, hormonal levels, glycemia, and insulin sensitivity at baseline and at the 3rd and 6th months of treatment." | 5.11 | Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. ( Ammini, AC; Dwivedi, SN; Eunice, M; Ganie, MA; Gulati, M; Gupta, N; Khurana, ML, 2004) |
| "This prospective clinical trial was designed to assess the effects of a long-term therapy with spironolactone, with and without dietary-induced weight-loss, on clinical features, lipid profile and insulin levels in women with polycystic ovary syndrome (PCOS)." | 5.11 | Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. ( Armanini, D; Baro, G; Benedini, S; Mantero, F; Sartorato, P; Scaroni, C; Zulian, E, 2005) |
| "To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)." | 5.11 | Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005) |
| "To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months." | 5.09 | Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000) |
| "Ferriman-Gallwey clinical score for hirsutism and serum testosterone, androstenedione, and LH levels." | 5.09 | Spironolactone as a single agent for long-term therapy of hirsute patients. ( Lhullier, F; Lisboa, KO; Mattiello, S; Spritzer, PM, 2000) |
| "This study explored the effect of the anti-androgen spironolactone on sex-hormone binding globulin (SHBG) and the distribution of circulating testosterone (T) into various free and bound fractions in seven women with hirsutism assessed before and then monthly for three months on a regimen of spironolactone, 100 mg bid as the sole therapeutic agent." | 5.08 | The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. ( Kirschner, MA; Lerário, AC; Luthold, WW; Marcondes, JA; Mendonça, BB; Minanni, SL; Nery, M; Wajchenberg, BL, 1995) |
| "To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone." | 4.82 | Spironolactone for hirsutism in polycystic ovary syndrome. ( Christy, NA; Cross, LB; Franks, AS, 2005) |
| "Retrospective analysis of 63 women with hyperandrogenic skin symptoms due to polycystic ovary syndrome (PCOS), treated with spironolactone for at least 6 months as first-line treatment." | 4.31 | Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. ( Andrisani, A; Armanini, D; Barbot, M; Beggiao, F; Belloni Fortina, A; Bordin, L; Ceccato, F; Donà, G; Keiko Vedolin, C; Orlando, G; Ragazzi, E; Sabbadin, C; Scaroni, C, 2023) |
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 4.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| "Altogether, the present study suggests that low-dose spironolactone confers protection against adipose dysfunction in experimental PCOS animals by attenuating inflammation, oxidative stress and cellular apoptosis." | 4.12 | Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. ( Areloegbe, SE; Olaniyi, KS; Oyeleke, MB; Peter, MU, 2022) |
| "The impact of low-dose spironolactone (LSPL) on polycystic ovarian syndrome (PCOS)-associated cardio-renal disorder is unknown." | 4.12 | Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. ( Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU, 2022) |
| "Spironolactone (SP) is an effective treatment for polycystic ovary syndrome (PCOS), but it is often associated with menstrual abnormalities whose mechanism is still under investigation." | 3.83 | Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. ( Ambrosini, G; Andrisani, A; Armanini, D; Bordin, L; Boscaro, M; Donà, G; Ragazzi, E; Sabbadin, C; Zermiani, M, 2016) |
| "The October 2010 ESHRE/ASRM polycystic ovary syndrome (PCOS) workshop concluded: (1) all combined oral contraceptives (COC) appear to have equal efficacy for PCOS, (2) addition of antiandrogens (spironolactone) to COCs has little treatment benefit and (3) metformin does not improve the live-birth rate and should only be used with impaired glucose tolerance." | 3.79 | Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. ( Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG, 2013) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| " 51 women completed a 6-month OCP trial (20 µg ethinyl estradiol + 75 µg gestodene, 21/28 days per cycle, plus 100 mg spironolactone in 32 women with moderate to severe hirsutism)." | 3.78 | Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women. ( Maier, PS; Spritzer, PM, 2012) |
| " The samples were all from patients with polycystic ovary syndrome taking 100-200 mg/d of a steroidal antiandrogen (spironolactone)." | 3.76 | Spironolactone interference in the immunoassay of androstenedione. ( Conway, GS; Dawnay, A; Honour, JW; Tsilchorozidou, T, 2010) |
| "To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period." | 3.75 | Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. ( Abbasi, M; Esteghamati, A; Hamidi, S; Nakhjavani, M; Nosratian-Jahromi, S; Pasalar, P, 2009) |
| "The research here reported concerns 9 hirsute women, four of them with PCO and five with idiopathic hirsutism, who underwent treatment with spironolactone." | 3.67 | Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. ( Ambrosio, GB; De Salvia, D; Gangemi, M; Grandesso, R; Meneghetti, G; Nardelli, GB; Predebon, O; Spandri, P, 1984) |
| "Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)." | 3.66 | Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981) |
| "The authors examined the effect of three months' treatment with spironolactone in 34 women with polycystic ovary syndrome." | 3.66 | Therapeutic effects of spironolactone in polycystic ovary syndrome. ( Kirschner, MA; Milewicz, A; Silber, D, 1983) |
| "Clinical and endocrine evaluations of 39 patients with hirsutism were performed to determine the effectiveness and site(s) of action of an antiandrogenic compound, spironolactone." | 3.66 | Treatment of hirsutism with spironolactone. ( Cumming, DC; Rebar, RW; Yang, JC; Yen, SS, 1982) |
| "Marked improvement in the severe hypertension (250/150 mmHg) and hirsutism of a patient suffering from polycystic ovary syndrome was quickly achieved by the use of spironolactone 200 mg per day." | 3.66 | Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. ( Blum, I; Chovers, I; Kaufman, H; Marilus, R; Rusecki, Y, 1981) |
| "The optimal drug for treatment with polycystic ovary syndrome (PCOS) was in debate." | 3.01 | Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis. ( Hao, SL; Meng, XY; Zhang, CL, 2023) |
| " Co-supplementation of high dosage VD with spironolactone or pioglitazone are more effective in reducing plasma leptin levels than metformin, and thus might prove to be better therapeutic strategies for women with PCOS." | 2.94 | Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study. ( Bhat, GA; Ganie, MA; Rashid, A; Shah, ZA; Shaheen, F; Shrivastava, M; Wani, IA, 2020) |
| " Thus, the primary objective of this study was to assess the effects on arterial function and structure of an OC containing chlormadinone acetate (2 mg) and ethinylestradiol (30 mcg), alone or combined with spironolactone (OC+SPL), in patients with PCOS." | 2.77 | The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. ( de Sá, MF; dos Reis, RM; Fernandes, JB; Ferriani, RA; Martins, WP; Soares, GM; Vieira, CS, 2012) |
| "Treatment with spironolactone normalized endothelial function and improved cholesterol levels in non-obese PCOS patients." | 2.76 | Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. ( Pfeifer, M; Prezelj, J; Sebestjen, M; Studen, KB, 2011) |
| "Polycystic ovary syndrome is the most common endocrinological problem associated with hirsutism." | 2.68 | Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. ( Gökmen, O; Gülekli, B; Işik, AZ; Senöz, S, 1996) |
| "(i) The term "female pattern hair loss" should be used, avoiding the previous terms of alopecia or androgenetic alopecia." | 2.61 | Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. ( Azziz, R; Bergfeld, W; Carmina, E; Escobar-Morreale, HF; Futterweit, W; Huddleston, H; Lobo, R; Olsen, E, 2019) |
| "Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female." | 2.61 | Hirsutism in Women. ( Bain, J; Matheson, E, 2019) |
| "Hirsutism is a common disorder with a major impact on quality of life." | 2.53 | Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments. ( Fedorowicz, Z; van Zuuren, EJ, 2016) |
| " The secondary outcome measures include acne scores, prevalence of dysglycaemia, BMI, lipid profile, total testosterone level, and adverse events." | 2.52 | The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Flórez, ID; Neupane, B; Thabane, L, 2015) |
| "Acne vulgaris is a common reason why adult women present to dermatologists and can be a clinical challenge to treat." | 2.48 | Acne in the adult female patient: a practical approach. ( Kamangar, F; Shinkai, K, 2012) |
| "Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women." | 2.46 | Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010) |
| "Idiopathic hirsutism is the second most common cause." | 2.44 | [Hirsutism]. ( Pijl, H; van Zuuren, EJ, 2007) |
| "Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy." | 2.43 | [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. ( Madsbad, S; Nilas, L; Nørgaard, K; Svendsen, PF, 2005) |
| "Although insulin resistance is not part of the diagnostic criteria for PCOS, its importance in the pathogenesis of PCOS can not be denied." | 2.43 | Insulin resistance in polycystic ovarian disease. ( Bhatia, V, 2005) |
| "The patient also had untreated Polycystic Ovarian Syndrome (PCOS)." | 2.41 | Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. ( Bauer, M; Carter, MS; Elman, S; Korenman, SG; Love, M; Rasgon, NL, 2002) |
| "Although hirsutism and androgenetic alopecia are cosmetic problems, they can be psychologically devastating for women." | 2.40 | Antiandrogen treatment of polycystic ovary syndrome. ( Rittmaster, RS, 1999) |
| "(Hirsutism is an off-label use of COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Polycystic ovary syndrome affects 7% of women of reproductive ages." | 1.62 | Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis. ( Dehghan, Z; Mirmotalebisohi, SA; Mohammadi-Yeganeh, S; Salehi, M; Sameni, M; Zali, H, 2021) |
| "Spironolactone (SPL) is a mineralocorticoid receptor (MR) blocker that has been in wide clinical use for some decades." | 1.56 | Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe. ( Adeyanju, OA; Agbana, RD; Falodun, TO; Michael, OS; Oyewole, AL; Soetan, OA, 2020) |
| "Successful treatment of hirsutism with combination OC+SPL requires at least 6 months of therapy, with the proportion of satisfied patients continuing to increase with treatment duration." | 1.48 | Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. ( Azziz, R; Ezeh, U; Huang, A; Landay, M, 2018) |
| "Polycystic ovary syndrome is the underlying cause in the vast majority of patients with hirsutism; however, it should be kept in mind that it can only be diagnosed after exclusion of some other diseases such as non-classical congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia and acromegaly." | 1.39 | Hirsutism - from diagnosis to use of antiandrogens. ( Karaca, Z; Kelestimur, F; Unluhizarci, K, 2013) |
| "The chronic migraine headaches almost completely disappeared shortly following therapy." | 1.39 | Dihydrotestosterone may contribute to the development of migraine headaches. ( Check, JH; Cohen, R, 2013) |
| "Patterned hair loss in men and women, although medically benign, is a common, albeit unwelcome, event that may cause considerable anxiety and concern." | 1.36 | Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. ( Rathnayake, D; Sinclair, R, 2010) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| " day of the cycle; Spironolactone (SPL) was given in a dosage of 100 mg/die from day 1." | 1.29 | [Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization]. ( Grunwald, K; Rabe, T; Runnebaum, B; Schlereth, G, 1994) |
| "Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome." | 1.27 | Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. ( Burke, CW; Evans, DJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (17.09) | 18.7374 |
| 1990's | 10 (8.55) | 18.2507 |
| 2000's | 22 (18.80) | 29.6817 |
| 2010's | 41 (35.04) | 24.3611 |
| 2020's | 24 (20.51) | 2.80 |
| Authors | Studies |
|---|---|
| Dehghan, Z | 1 |
| Mohammadi-Yeganeh, S | 1 |
| Sameni, M | 1 |
| Mirmotalebisohi, SA | 1 |
| Zali, H | 1 |
| Salehi, M | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Sabbadin, C | 2 |
| Beggiao, F | 1 |
| Keiko Vedolin, C | 1 |
| Orlando, G | 1 |
| Ragazzi, E | 2 |
| Ceccato, F | 1 |
| Barbot, M | 1 |
| Bordin, L | 2 |
| Donà, G | 2 |
| Andrisani, A | 2 |
| Belloni Fortina, A | 1 |
| Scaroni, C | 3 |
| Armanini, D | 5 |
| Peter, MU | 2 |
| Areloegbe, SE | 3 |
| Akintayo, CO | 1 |
| Oniyide, AA | 2 |
| Aturamu, A | 1 |
| Olaniyi, KS | 4 |
| Oyeleke, MB | 1 |
| Garcia-Beltran, C | 5 |
| Bassols, J | 3 |
| Carreras-Badosa, G | 1 |
| López Bermejo, A | 1 |
| Ibáñez, L | 9 |
| de Zegher, F | 9 |
| Bashir, R | 1 |
| Asrar, MM | 1 |
| Shah, IA | 1 |
| Wani, IA | 4 |
| Ganie, MA | 6 |
| Areola, ED | 1 |
| Sabinari, IW | 1 |
| Fafure, AA | 1 |
| Agbana, RD | 2 |
| Atuma, CL | 1 |
| Shah, MZUH | 1 |
| Ajadi, IO | 1 |
| Olatunji, LA | 2 |
| Zeng, H | 1 |
| Zhang, Y | 1 |
| Huang, S | 1 |
| Wu, J | 1 |
| Ren, W | 1 |
| Zhou, L | 1 |
| Huang, L | 1 |
| Ye, Y | 1 |
| Malpique, R | 4 |
| Andersen, MS | 1 |
| Bas, F | 1 |
| Darendeliler, F | 1 |
| Díaz, M | 4 |
| Dieris, B | 1 |
| Fanelli, F | 1 |
| Fröhlich-Reiterer, E | 1 |
| Gambineri, A | 1 |
| Glintborg, D | 1 |
| López-Bermejo, A | 7 |
| Mann, C | 1 |
| Marin, S | 1 |
| Obermayer-Pietsch, B | 1 |
| Ødegård, R | 1 |
| Ravn, P | 1 |
| Reinehr, T | 1 |
| Renzulli, M | 1 |
| Salvador, C | 1 |
| Singer, V | 1 |
| Vanky, E | 1 |
| Torres, JV | 1 |
| Yildiz, M | 1 |
| Hao, SL | 1 |
| Zhang, CL | 1 |
| Meng, XY | 1 |
| Basu, P | 1 |
| Elman, SA | 1 |
| Abudu, B | 1 |
| Beckles, A | 1 |
| Salian, P | 1 |
| Yanes, DA | 1 |
| Porter, ML | 1 |
| Reynolds, RV | 2 |
| Rashid, A | 2 |
| Sood, M | 1 |
| Sofi, NY | 1 |
| Nisar, S | 2 |
| Butt, TP | 1 |
| Gupta, N | 4 |
| Bhat, D | 1 |
| Choh, N | 1 |
| Masoodi, SR | 1 |
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Amar, J | 1 |
| Angoulvant, T | 1 |
| Boivin, JM | 1 |
| Amar, L | 1 |
| Lantelme, P | 1 |
| Blacher, J | 1 |
| Plu-Bureau, G | 1 |
| Vehier, CM | 1 |
| Adeyanju, OA | 3 |
| Falodun, TO | 2 |
| Michael, OS | 1 |
| Soetan, OA | 1 |
| Oyewole, AL | 1 |
| Bhat, GA | 1 |
| Shaheen, F | 1 |
| Shrivastava, M | 1 |
| Shah, ZA | 2 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Villarroya, F | 2 |
| Almalki, HH | 1 |
| Alshibani, TM | 1 |
| Alhifany, AA | 1 |
| Almohammed, OA | 1 |
| Kfoury, B | 1 |
| Cohen, JB | 1 |
| Carbonetto, B | 1 |
| González-Torres, P | 1 |
| Henares, D | 1 |
| Brotons, P | 1 |
| Muñoz-Almagro, C | 1 |
| Ojulari, LS | 1 |
| Omoaghe, AO | 1 |
| Olaiya, OE | 1 |
| Villarroya, J | 1 |
| Cairó, M | 1 |
| Del Río, L | 1 |
| Sebastiani, G | 1 |
| Pozo, ÓJ | 1 |
| Alpañés, M | 1 |
| Álvarez-Blasco, F | 1 |
| Fernández-Durán, E | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 2 |
| Ezeh, U | 1 |
| Huang, A | 1 |
| Landay, M | 1 |
| Azziz, R | 2 |
| Muneyyirci-Delale, O | 2 |
| Co, S | 1 |
| Winer, N | 1 |
| Azarchi, S | 1 |
| Bienenfeld, A | 1 |
| Lo Sicco, K | 1 |
| Marchbein, S | 1 |
| Shapiro, J | 1 |
| Nagler, AR | 1 |
| Uliassi, N | 1 |
| Sullivan, S | 1 |
| Damle, L | 1 |
| Gomez-Lobo, V | 2 |
| Sánchez-Infantes, D | 1 |
| Taxerås, SD | 1 |
| Carmina, E | 1 |
| Bergfeld, W | 1 |
| Futterweit, W | 1 |
| Huddleston, H | 1 |
| Lobo, R | 1 |
| Olsen, E | 1 |
| Fabunmi, OA | 1 |
| Soladoye, AO | 1 |
| Matheson, E | 1 |
| Bain, J | 1 |
| Kaplan, J | 1 |
| Joulak, I | 1 |
| Yang, L | 1 |
| Von Gizycki, H | 1 |
| Nacharaju, VL | 1 |
| Mazza, A | 1 |
| Fruci, B | 1 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 1 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 1 |
| Khurana, ML | 2 |
| Shah, PA | 1 |
| Kulshrestha, B | 1 |
| Zargar, MA | 1 |
| Wani, TA | 1 |
| Mudasir, S | 1 |
| Mir, FA | 1 |
| Taing, S | 1 |
| Check, JH | 1 |
| Cohen, R | 1 |
| Unluhizarci, K | 2 |
| Karaca, Z | 2 |
| Kelestimur, F | 2 |
| Dăneasă, A | 1 |
| Cucolaș, C | 1 |
| Furcea, M | 1 |
| Bolfa, P | 1 |
| Dudea, S | 1 |
| Olteanu, D | 1 |
| Alupei, MC | 1 |
| Mureșan, A | 1 |
| Filip, GA | 1 |
| Leelaphiwat, S | 1 |
| Jongwutiwes, T | 1 |
| Lertvikool, S | 1 |
| Tabcharoen, C | 1 |
| Sukprasert, M | 1 |
| Rattanasiri, S | 1 |
| Weerakiet, S | 1 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| Moreno, LE | 1 |
| Bonnell, A | 1 |
| Neher, JO | 1 |
| Safranek, S | 1 |
| Diri, H | 1 |
| Karaburgu, S | 1 |
| Acmaz, B | 1 |
| Tanriverdi, F | 1 |
| Al Khalifah, RA | 1 |
| Flórez, ID | 1 |
| Dennis, B | 1 |
| Neupane, B | 1 |
| Thabane, L | 1 |
| Bassilious, E | 1 |
| van Zuuren, EJ | 2 |
| Fedorowicz, Z | 1 |
| Kulshreshtha, B | 2 |
| Arora, A | 1 |
| Pahuja, I | 1 |
| Sharma, N | 1 |
| Pant, S | 1 |
| Zermiani, M | 1 |
| Boscaro, M | 1 |
| Ambrosini, G | 1 |
| Friedman, AJ | 1 |
| Kebapcilar, L | 2 |
| Taner, CE | 3 |
| Kebapcilar, AG | 2 |
| Alacacioglu, A | 2 |
| Sari, I | 2 |
| Bilgir, O | 1 |
| Kozaci, DL | 1 |
| Yildiz, Y | 1 |
| Yuksel, A | 1 |
| Nakhjavani, M | 1 |
| Hamidi, S | 1 |
| Esteghamati, A | 1 |
| Abbasi, M | 1 |
| Nosratian-Jahromi, S | 1 |
| Pasalar, P | 1 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Brodell, LA | 1 |
| Mercurio, MG | 2 |
| Rathnayake, D | 1 |
| Sinclair, R | 1 |
| Honour, JW | 1 |
| Tsilchorozidou, T | 1 |
| Conway, GS | 1 |
| Dawnay, A | 1 |
| Studen, KB | 1 |
| Sebestjen, M | 1 |
| Pfeifer, M | 1 |
| Prezelj, J | 1 |
| Maier, PS | 2 |
| Mattiello, SS | 1 |
| Lages, L | 1 |
| Spritzer, PM | 3 |
| Vieira, CS | 1 |
| Martins, WP | 1 |
| Fernandes, JB | 1 |
| Soares, GM | 1 |
| dos Reis, RM | 1 |
| de Sá, MF | 1 |
| Ferriani, RA | 1 |
| Ammini, AC | 2 |
| Harmanci, A | 1 |
| Cinar, N | 1 |
| Bayraktar, M | 1 |
| Yildiz, BO | 2 |
| Bonny, AE | 1 |
| Appelbaum, H | 1 |
| Connor, EL | 1 |
| Cromer, B | 1 |
| DiVasta, A | 1 |
| Harel, Z | 1 |
| Huppert, J | 1 |
| Sucato, G | 1 |
| Kamangar, F | 1 |
| Shinkai, K | 1 |
| Bird, ST | 1 |
| Hartzema, AG | 1 |
| Etminan, M | 1 |
| Brophy, JM | 1 |
| Delaney, JA | 1 |
| Amesse, LS | 1 |
| Ding, X | 1 |
| Pfaff-Amesse, T | 1 |
| Rasgon, NL | 1 |
| Carter, MS | 1 |
| Elman, S | 1 |
| Bauer, M | 1 |
| Love, M | 1 |
| Korenman, SG | 1 |
| Schroeder, BM | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Eunice, M | 1 |
| Gulati, M | 1 |
| Dwivedi, SN | 1 |
| Zulian, E | 1 |
| Sartorato, P | 1 |
| Benedini, S | 1 |
| Baro, G | 1 |
| Mantero, F | 1 |
| Al-Inany, H | 2 |
| Christy, NA | 1 |
| Franks, AS | 1 |
| Cross, LB | 1 |
| Svendsen, PF | 1 |
| Nilas, L | 1 |
| Nørgaard, K | 1 |
| Madsbad, S | 1 |
| Bhatia, V | 1 |
| Fleischman, A | 1 |
| Mansfield, J | 1 |
| Inal, MM | 1 |
| Yildirim, Y | 1 |
| Castello, R | 3 |
| Bonanni, G | 1 |
| Faccini, G | 1 |
| Pellati, D | 2 |
| Bertoldo, A | 1 |
| Fiore, C | 2 |
| Moghetti, P | 3 |
| Pijl, H | 1 |
| Rajput, R | 1 |
| Bhansali, A | 1 |
| Singh, R | 1 |
| De Pedrini, P | 1 |
| Suraci, C | 1 |
| Costa, C | 1 |
| Shoupe, D | 1 |
| Lobo, RA | 2 |
| Raj, SG | 1 |
| Talbert, LM | 1 |
| Coney, P | 1 |
| Spandri, P | 1 |
| Gangemi, M | 1 |
| Nardelli, GB | 1 |
| Meneghetti, G | 1 |
| Grandesso, R | 1 |
| De Salvia, D | 1 |
| Ambrosio, GB | 1 |
| Predebon, O | 1 |
| Evron, S | 1 |
| Yosef, SM | 1 |
| Schenker, JG | 1 |
| Diamant, YZ | 1 |
| Milewicz, A | 4 |
| Grabiński, M | 3 |
| Tupikowska, G | 2 |
| Szymczak, J | 1 |
| Junkermann, H | 1 |
| Silber-Kasprzak, D | 1 |
| Checińska, E | 1 |
| Silber, D | 1 |
| Kirschner, MA | 2 |
| Mitra, K | 1 |
| Chaudhuri, N | 1 |
| Kundu, D | 1 |
| Mondal, S | 1 |
| Ghose, D | 1 |
| Cumming, DC | 1 |
| Yang, JC | 1 |
| Rebar, RW | 1 |
| Yen, SS | 1 |
| Blum, I | 2 |
| Kaufman, H | 2 |
| Marilus, R | 1 |
| Rusecki, Y | 1 |
| Chovers, I | 1 |
| Bruhis, S | 1 |
| Marcondes, JA | 1 |
| Minanni, SL | 1 |
| Luthold, WW | 1 |
| Lerário, AC | 1 |
| Nery, M | 1 |
| Mendonça, BB | 1 |
| Wajchenberg, BL | 1 |
| Dunaif, A | 1 |
| Vĕtr, M | 1 |
| Sobek, A | 1 |
| Grunwald, K | 1 |
| Rabe, T | 1 |
| Schlereth, G | 1 |
| Runnebaum, B | 1 |
| Gökmen, O | 1 |
| Senöz, S | 1 |
| Gülekli, B | 1 |
| Işik, AZ | 1 |
| Koloszár, S | 1 |
| Szöllösi, J | 1 |
| Bártfai, G | 1 |
| Zamberlan, N | 1 |
| Rossini, M | 1 |
| Gatti, D | 1 |
| Negri, C | 2 |
| Tosi, F | 2 |
| Muggeo, M | 2 |
| Adami, S | 1 |
| Rittmaster, RS | 1 |
| Tosti, A | 1 |
| Misciali, C | 1 |
| Perrone, F | 1 |
| Caputo, M | 1 |
| Lisboa, KO | 1 |
| Mattiello, S | 1 |
| Lhullier, F | 1 |
| Elkind-Hirsch, KE | 1 |
| Valdes, CT | 1 |
| McConnell, TG | 1 |
| Malinak, LR | 1 |
| McKenna, KM | 1 |
| Pepperell, RJ | 1 |
| Evans, J | 1 |
| Bolanowski, M | 1 |
| Zalewski, J | 1 |
| Pittaway, DE | 1 |
| Maxson, WS | 1 |
| Wentz, AC | 1 |
| Siegberg, R | 1 |
| Ylöstalo, P | 1 |
| Laatikainen, T | 1 |
| Pelkonen, R | 1 |
| Stenman, UH | 1 |
| Ohkochi, T | 1 |
| Tanaka, T | 1 |
| Oikawa, M | 1 |
| Sakuragi, N | 1 |
| Fujimoto, S | 1 |
| Ichinoe, K | 1 |
| Evans, DJ | 1 |
| Burke, CW | 1 |
| Morris, DV | 1 |
| Serafini, PC | 1 |
| Catalino, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia[NCT05888922] | Phase 3 | 520 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| 17-hydroxysteroid Dehydrogenase Type 5 Gene Polymorphism (71A/G HSD17B5 SNP) and Effects of Oral Contraceptive Pill on Hirsutism, Androgens and Metabolic Profile in Non-obese PCOS Women: a Pilot Study[NCT01372293] | 49 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Topical Silymarin Cream Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: Split Face Study[NCT04490967] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-04-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for spironolactone and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis.
Topics: Androgen Antagonists; Female; Finasteride; Hirsutism; Humans; Polycystic Ovary Syndrome; Spironolact | 2023 |
Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Follicle Stimulating Hormone, Human; Hirsut | 2023 |
Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis.
Topics: Atorvastatin; Female; Humans; Metformin; Network Meta-Analysis; Polycystic Ovary Syndrome; Simvastat | 2023 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Topics: Age Factors; Antihypertensive Agents; Blood Pressure; Breast Neoplasms; Female; Humans; Hypertension | 2019 |
Androgens in women: Hormone-modulating therapies for skin disease.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Alopecia; Androgen Ant | 2019 |
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Humans; Hyperandrogenism; Low- | 2019 |
Hirsutism in Women.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Antineoplastic Agents, Hormonal; Contraceptiv | 2019 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
Clinical Inquiry: What therapies alleviate symptoms of polycystic ovary syndrome?
Topics: Body Mass Index; Contraceptives, Oral; Diuretics; Female; Humans; Hydroxymethylglutaryl-CoA Reductas | 2015 |
The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Diet; Drug Therapy, Combination; Exercise; F | 2015 |
Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Androgen Antagonists; Body Mass Index; Contraceptives, Ora | 2016 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Hirsutism: Diagnosis and management.
Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag | 2010 |
Acne in the adult female patient: a practical approach.
Topics: Acne Vulgaris; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral, Hormonal; Dermatologic | 2012 |
Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combinati | 2002 |
Polycystic ovary syndrome.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Fin | 2004 |
Spironolactone for hirsutism in polycystic ovary syndrome.
Topics: Female; Hirsutism; Humans; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spiron | 2005 |
[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; | 2005 |
Insulin resistance in polycystic ovarian disease.
Topics: Cardiovascular Diseases; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inflamma | 2005 |
Polycystic ovary syndrome.
Topics: Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Finasteride; Flutamide; H | 2005 |
[Hirsutism].
Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Cyproterone Acetate; Female; Hirsutism; Human | 2007 |
Polycystic ovarian disease.
Topics: Adrenal Hyperplasia, Congenital; Androgens; Chorionic Gonadotropin; Cimetidine; Clomiphene; Contrace | 1984 |
Polycystic ovarian disease: current concepts of pathophysiology and therapy.
Topics: 17-Ketosteroids; Adrenal Cortex; Adrenal Glands; Androgen Antagonists; Androstenedione; Animals; Cim | 1984 |
Antiandrogen treatment of polycystic ovary syndrome.
Topics: Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirs | 1999 |
Hirsutism: diagnosis and management.
Topics: Adrenal Hyperplasia, Congenital; Androgens; Contraceptives, Oral; Eflornithine; Enzyme Inhibitors; F | 2001 |
Hirsutism.
Topics: Adrenal Glands; Adrenal Hyperplasia, Congenital; Adrenocortical Hyperfunction; Androgens; Cimetidine | 1985 |
32 trials available for spironolactone and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a mult
Topics: Adolescent; Carotid Intima-Media Thickness; Clinical Trials, Phase II as Topic; Female; Humans; Insu | 2023 |
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Indi | 2020 |
Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments.
Topics: Adolescent; Biomarkers; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemi | 2020 |
Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study.
Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Leptin; Metformin; Pioglitazone; | 2020 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 1 | 2021 |
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F | 2017 |
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
Topics: Adult; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Hirsutism; Humans; Hypo | 2017 |
Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials.
Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Contraceptives, Oral; Drug Therapy, Combination; Fem | 2019 |
Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone.
Topics: Adolescent; Adult; Aldosterone; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Human | 2013 |
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Composition; Body Mass Index; Drug Therapy, C | 2013 |
Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Androgens; Androstenedione; Cholesterol; Contraceptives, | 2015 |
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com | 2016 |
Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Topics: Adult; Blood Coagulation; Cyproterone Acetate; Estrogens; Ethinyl Estradiol; Female; Fibrin Fibrinog | 2010 |
Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients.
Topics: Adolescent; Adult; CD40 Antigens; Contraceptives, Oral, Combined; Cyproterone Acetate; Drug Therapy, | 2010 |
Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.
Topics: Adult; Aldosterone; Androgen Antagonists; Androgens; Androstenedione; Dehydroepiandrosterone Sulfate | 2011 |
17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
Topics: 3-Hydroxysteroid Dehydrogenases; Adolescent; Adult; Aldo-Keto Reductase Family 1 Member C3; Brazil; | 2012 |
The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries | 2012 |
Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
Topics: Adolescent; Adult; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformi | 2004 |
Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.
Topics: Adolescent; Adult; Androgen Antagonists; Area Under Curve; Body Mass Index; Caloric Restriction; Die | 2005 |
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Diuretics; Drug Combinations; Drug Therapy, Combin | 2005 |
Treatment of polycystic ovary syndrome with spironolactone plus licorice.
Topics: Adult; Aldosterone; Androgens; Blood Pressure; Diuretics; Drug Therapy, Combination; Female; Glycyrr | 2007 |
The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women.
Topics: Adolescent; Adult; Body Weight; Dehydroepiandrosterone; Estradiol; Female; Hirsutism; Hormone Antago | 1995 |
Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
Topics: Adolescent; Adult; Female; Hirsutism; Humans; Hyperandrogenism; Infant, Newborn; Luteinizing Hormone | 1993 |
Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Contrac | 1996 |
[Ovulation induction with adjuvant antiandrogen treatment in Stein-Leventhal syndrome].
Topics: Adult; Androgen Antagonists; Anovulation; Cyproterone Acetate; Dexamethasone; Female; Humans; Hypera | 1996 |
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Topics: Adult; Bone and Bones; Bone Density; Bone Resorption; Female; Flutamide; Hirsutism; Humans; Polycyst | 1999 |
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
Topics: Adult; Androgen Antagonists; Double-Blind Method; Female; Finasteride; Flutamide; Hair; Hirsutism; H | 2000 |
Spironolactone as a single agent for long-term therapy of hirsute patients.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenedione; Cyproterone Acetate; Drug Therapy, Combina | 2000 |
Induction of ovulation by pulsatile LH-RH administration in polycystic ovarian syndrome.
Topics: Anovulation; Drug Therapy, Combination; Female; Gonadotropin-Releasing Hormone; Humans; Infertility, | 1989 |
Endocrine and clinical effects of spironolactone in female hyperandrogenism.
Topics: Adult; Amenorrhea; Androgens; Double-Blind Method; Endocrine System Diseases; Female; Gonadotropins, | 1987 |
58 other studies available for spironolactone and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis.
Topics: Computational Biology; Databases, Protein; Drug Repositioning; Female; Gene Expression Regulation; H | 2021 |
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders.
Topics: Female; Hirsutism; Humans; Neoplasm Recurrence, Local; Polycystic Ovary Syndrome; Quality of Life; R | 2023 |
Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
Topics: Animals; bcl-2-Associated X Protein; Disease Models, Animal; Female; Humans; Inflammasomes; Letrozol | 2022 |
Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.
Topics: Adipose Tissue; Animals; Apoptosis; Female; Humans; Inflammation; Letrozole; Polycystic Ovary Syndro | 2022 |
Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlle | 2023 |
Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
Topics: Animals; Dyslipidemias; Female; Humans; Inflammation; Letrozole; NLR Family, Pyrin Domain-Containing | 2023 |
High-dose spironolactone for acne in patients with polycystic ovarian syndrome: A single-institution retrospective study.
Topics: Acne Vulgaris; Female; Hirsutism; Humans; Mineralocorticoid Receptor Antagonists; Polycystic Ovary S | 2021 |
Polycystic ovary syndrome in adolescent girls.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone | 2020 |
Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe.
Topics: Animals; Female; Letrozole; Liver; Ovary; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolact | 2020 |
Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials.
Topics: Contraceptives, Oral, Combined; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypo | 2020 |
Elevated Renin and Aldosterone Levels in a Young Woman With Hypertension.
Topics: Adult; Aldosterone; Androstenes; Antihypertensive Agents; Computed Tomography Angiography; Contracep | 2020 |
Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments.
Topics: Adolescent; Female; Gastrointestinal Microbiome; Humans; Metformin; Pioglitazone; Polycystic Ovary S | 2021 |
Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
Topics: Adiponectin; Animals; Biomarkers; Disease Models, Animal; Female; Inflammation Mediators; Letrozole; | 2021 |
Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.
Topics: Contraceptives, Oral; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hirsutism; Humans; | 2018 |
Vascular compliance in women with polycystic ovary syndrome treated with spironolactone.
Topics: Adult; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Elasticity; Female; Glucose Intoler | 2018 |
Trends, in Diagnosis and Treatment of Polycystic Ovarian Syndrome by Specialty.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Diagnostic Tests, Routine; Diuretics; Endocrinolo | 2016 |
Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.
Topics: Androgen Antagonists; Animals; Female; Insulin Resistance; Letrozole; Luteinizing Hormone; Mineraloc | 2019 |
Dihydrotestosterone may contribute to the development of migraine headaches.
Topics: 5-alpha Reductase Inhibitors; Contraceptives, Oral; Dextroamphetamine; Dihydrotestosterone; Female; | 2013 |
Hirsutism - from diagnosis to use of antiandrogens.
Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsutism; H | 2013 |
Spironolactone and dimethylsulfoxide effect on glucose metabolism and oxidative stress markers in polycystic ovarian syndrome rat model.
Topics: Animals; Antioxidants; Biomarkers; Dimethyl Sulfoxide; Diuretics; Estradiol; Female; Glucose; Glucos | 2014 |
Menstrual cyclicity post OC withdrawal in PCOS: Use of non-hormonal options.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; Menstrual Cy | 2016 |
Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.
Topics: Adult; Body Mass Index; Female; Humans; Menstrual Cycle; Metrorrhagia; Mineralocorticoid Receptor An | 2016 |
Spironolactone for
Adult Female Acne.
Topics: Acne Vulgaris; Adult; Female; Humans; Menstrual Cycle; Mineralocorticoid Receptor Antagonists; Polyc | 2015 |
Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.
Topics: Adolescent; Adult; Child; Cholesterol, HDL; Cholesterol, LDL; Female; Hirsutism; Humans; Lipids; Min | 2009 |
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
Topics: Adolescent; Adult; Alopecia; Androgen Antagonists; Female; Humans; Male; Middle Aged; Minoxidil; Off | 2010 |
Spironolactone interference in the immunoassay of androstenedione.
Topics: Androstenedione; Female; Humans; Immunoassay; Polycystic Ovary Syndrome; Spironolactone | 2010 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
Topics: Adult; Androstenes; C-Reactive Protein; Cholesterol, HDL; Ethinyl Estradiol; Fasting; Female; Glucos | 2013 |
Clinical variability in approaches to polycystic ovary syndrome.
Topics: Adolescent; Contraceptives, Oral; Cross-Sectional Studies; Data Collection; Exercise; Feeding Behavi | 2012 |
Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
Topics: Adult; Androgens; Anovulation; Aromatase; Blood Pressure; Body Mass Index; Contraceptives, Oral; Eth | 2012 |
Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines.
Topics: Androgen Antagonists; Contraceptives, Oral, Combined; Databases, Factual; Drug Prescriptions; Female | 2013 |
From HAIR-AN to eternity.
Topics: Acanthosis Nigricans; Child; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Polycy | 2002 |
ACOG releases guidelines on diagnosis and management of polycystic ovary syndrome.
Topics: Adrenal Hyperplasia, Congenital; Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Humans; Mi | 2003 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Diagnosis and treatment of polycystic ovarian syndrome and insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperandrogenism; Hyperlipidemia | 2005 |
Polycystic ovary syndrome: implications of corticotropin in the regulation of blood pressure, aldosterone, and androgen secretion.
Topics: Adrenocorticotropic Hormone; Aldosterone; Biomarkers; Blood Pressure; Female; Humans; Hypertension; | 2007 |
Assessment, diagnosis and treatment of a patient with hirsutism.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Ethinyl Estradiol; Female; Hirsutism; Humans; Poly | 2008 |
Ovarian hyperthecosis and response to antiandrogens: An uncommon presentation of a common disorder.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral, Hormonal; Female; Humans; Polycystic Ovary S | 2008 |
[Therapy of female hirsutism: current status and new findings].
Topics: Adrenal Cortex Hormones; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Bromocrip | 1983 |
The influence of androgens on insulin resistance.
Topics: Adult; Androgens; Androstane-3,17-diol; Dehydroepiandrosterone; Dihydrotestosterone; Female; Hirsuti | 1984 |
Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy.
Topics: 17-Ketosteroids; Adolescent; Adult; Estradiol; Female; Follicle Stimulating Hormone; Hirsutism; Huma | 1984 |
Effect of spironolactone on testosterone and LHRH responsiveness in women with polycystic ovarian disease.
Topics: Adult; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Lute | 1984 |
[Use of spironolactone in the treatment of women with polycystic ovary syndrome associated with hyperprolactinemia].
Topics: Adult; Female; Follow-Up Studies; Humans; Polycystic Ovary Syndrome; Prolactin; Spironolactone | 1984 |
[Therapeutic effects of diethylstilbestrol and spironolactone in polycystic ovary syndrome].
Topics: Adult; Diethylstilbestrol; Drug Therapy, Combination; Female; Humans; Ovulation Induction; Polycysti | 1984 |
Therapeutic effects of spironolactone in polycystic ovary syndrome.
Topics: Adult; Female; Hirsutism; Humans; Menstruation Disturbances; Pituitary Hormones; Polycystic Ovary Sy | 1983 |
Hirsutism and problem of its management.
Topics: Adolescent; Adult; Allylestrenol; Dexamethasone; Ethinyl Estradiol; Female; Hirsutism; Humans; Polyc | 1982 |
Treatment of hirsutism with spironolactone.
Topics: Amenorrhea; Androgen Antagonists; Androgens; Androstenedione; Cytochrome P-450 Enzyme Inhibitors; Fa | 1982 |
Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine.
Topics: Adult; Bromocriptine; Female; Hirsutism; Hormones; Humans; Hypertension; Polycystic Ovary Syndrome; | 1981 |
Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome.
Topics: Adult; Blood Pressure; Body Weight; Bromocriptine; Drug Therapy, Combination; Female; Glucose Tolera | 1981 |
Polycystic ovary syndrome.
Topics: Clomiphene; Contraceptives, Oral; Drug Therapy, Combination; Female; Glucocorticoids; Gonadotropin-R | 1994 |
[Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization].
Topics: Adult; Androgen Antagonists; Androgens; Cyproterone Acetate; Dose-Response Relationship, Drug; Drug | 1994 |
Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women.
Topics: Adrenal Glands; Adult; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Fo | 1991 |
Hirsutism in a gynaecological context.
Topics: Adult; Anovulation; Contraceptives, Oral, Hormonal; Female; Gonadal Steroid Hormones; Hirsutism; Hum | 1990 |
Spironolactone in combination drug therapy for unresponsive hirsutism.
Topics: Contraceptives, Oral; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Drug Th | 1985 |
[Effects of ovarian wedge resection (WR) and spironolactone administration on pulsatile LH release and serum steroid hormone levels in women with polycystic ovarian disease].
Topics: Adult; Androstenes; Estrenes; Female; Humans; Luteinizing Hormone; Ovary; Ovulation Induction; Polyc | 1987 |
Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Hirsutism; Humans; Menstruation Disturbances; Middle Aged; Polycystic Ova | 1986 |
The effect of spironolactone on genital skin 5 alpha-reductase activity.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adult; Female; Hirsutism; Humans; Kinetics; Oxidoreductases; | 1985 |